Date: 2016-03-29
Type of information: Series A financing round
Company: Gadeta (The Netherlands)
Investors: Baxalta Ventures (USA - MA) Utrecht Holdings (The Netherlands) Medicxi Ventures (Switzerland) founders and management
Amount: € 7 million
Funding type: series A financing round
Planned used: Founded in 2015, Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (??) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity. These novel cancer immunotherapies are based on the discoveries of Prof. Dr. Jürgen Kuball regarding the role of ?? T cell receptors in the broad recognition of the metabolic differences in hematological and solid tumor cells, and their potential use for the treatment of advanced malignancies. Gadeta will use the funds to accelerate its programs and rapidly advance them to the clinic. The company expects to start a Phase I/IIa clinical trial of its lead program in acute myeloid leukemia (AML) in early 2017. In parallel, the company intends to optimize a closed manufacturing system to allow for the start of a second clinical trial in solid tumors later in 2017
Others: * On March 29, 2016, Gadeta, a Dutch start-up company focused on the discovery and development of novel cancer
immunotherapies based on gamma delta (??) T cell receptors, announced the completion of a € 7 million Series A financing round led by Baxalta Ventures and Medicxi Ventures. Founders, management and Utrecht Holdings also participated. Geeta Vemuri from Baxalta Ventures and Michèle Ollier and Giovanni Mariggi from Medicxi Ventures will join the supervisory board. The company was founded by Dr. Jürgen Kuball, Mark de Boer, Utrecht Holdings and Medicxi Ventures (which provided seed capital).
Therapeutic area: Cancer - Oncology
